Drugs / HRS2300
last change May 2023 re-read 2 minutes ago

HRS2300

Developed for
cancer
Investigated by
Jiangsu HengRui Medicine Co., Ltd.

Trials 1 · a red edge is where a trial was stopped

20222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT05048134 Oct 2021 → Feb 2023 cancer Jiangsu HengRui Medicine Co., Ltd. Terminated No outcome recorded

Evidence & citations 1 cited value

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as HRS2300 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05048134